Business
Announces US FDA Approval of Speedboat RS2
Announces US FDA Approval of Speedboat RS2.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \nRNS Number : 4701O Creo Medical Group PLC 21 August 2017 \n\nCreo Medical Group plc\n(\"Creo\" or \"the Company\")\n \nAnnounces US FDA Approval of Speedboat RS2\n \nApproval comes ahead of schedule; Company to implement commercial plans\n \nChepstow, South Wales - 21 August 2017 - Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announces that it has received 510(k) clearance (\"FDA Clearance\") from the US Food and Drug Administration (\"FDA\") for its Speedboat RS2 device and the CROMA platform.\n \nSpeedboat RS2 is the first of a range of medical devices in development, powered by the CROMA platform, and enables the minimally invasive removal of early stage cancerous and pre-cancerous lesions in the bowel through an endoscopic procedure. This FDA Clearance has been received ahead of schedule, with the FDA review process being completed in 49 calendar days from submission. Accordingly, Creo will now assess the necessary steps to bring forward the implementation of its commercial plans for the US.\n \nSpeedboat RS2 is the first device developed for use with the Company's generator, CROMA. It harnesses the cut and coagulation capability of CROMA and enables the removal of early stage cancerous and pre-cancerous lesions. The use of Speedboat RS2 reduces the risks associated with incisions which are necessary for laparoscopic procedures and can reduce the length of hospital stay. Endoscopy has been a rapidly expanding practice due to the advent of colorectal cancer screening in most healthcare systems. This has driven growth in equipment and devices to enhance the ability to screen and detect early stage and pre-cancerous lesions in the GI tract.\n \nIn the US, over 16 million colonoscopies are performed annually. Of these, 1.1 million are likely to find a lesion requiring treatment, half of which are surgically removed. Traditional colorectal surgery is associated with a 6 per cent mortality rate at 30 days. Due to Speedboat RS2's ability to coagulate bleeding vessels when the microwave energy is activated by the surgeon, and to cut or resect when the RF energy is activated, the risk of puncturing tissue could be reduced, offering surgeons a minimally invasive alternative with an enhanced safety profile.\n \nCraig...